Currently Viewing:
Currently Reading
What We're Reading: Orphan Drugs in 340B and the Hospital "Weekend Effect"
October 16, 2015 – AJMC Staff
Predicting Incident Bone Fractures in Type 1 Diabetes Patients
October 15, 2015 – AJMC Staff
What We're Reading: Biosimilar Reimbursement and Scrutinizing Drug Pricing
October 15, 2015 – AJMC Staff
What's Behind the Obesity Paradox?
October 14, 2015 – Mary K. Caffrey
What We're Reading: Replacing the ACA and Opioid Addiction Treatment
October 14, 2015 – AJMC Staff
US Continues to Have Worse Health Outcomes Than Comparable Countries
October 13, 2015 – Laura Joszt
Glass of Red Wine Won't Hurt Those With Diabetes, and May Help
October 13, 2015 – Mary K. Caffrey
What We're Reading: Presidential Campaigns and the Cost of Medicine
October 13, 2015 – AJMC Staff
What We're Reading: Health Insurance Coverage and Unecessary Procedures
October 12, 2015 – AJMC Staff

What We're Reading: Orphan Drugs in 340B and the Hospital "Weekend Effect"

AJMC Staff
What we're reading, October 16, 2015: judge rules orphan drugs do not need to be sold at discount under 340B, hospitals can use resources at their disposal to overcome the "weekend effect," and AstraZeneca's diabetes combination drug fails to win FDA approval.
Orphan Drugs Excluded From 340B Program

A judge ruled that orphan drugs do not need to be sold at a discount to rural and cancer hospitals under the 340B drug discount program. While the pharmaceutical industry viewed the ruling as a victory, many hospitals say the decision could lead to higher prices for patients and could limit access to some medications, according to Modern Healthcare.

Read more:

Overcoming the “Weekend Effect” at Hospitals

Hospitals can overcome the so-called “weekend effect,” in which outcomes are worse for patients undergoing emergent/urgent surgeries on the weekend compared with weekdays, through the use of specific hospital resources, according to a study published in the Annals of Surgery. Resources that were predictors for overcoming the weekend effect include full adoption of electronic medical records, pain management programs, and an increased registered nurse-to-bed ratio.

Read more:

New Diabetes Treatment Fails to Win Approval

The FDA declined to approve AstraZeneca Plc’s new diabetes treatment that combines 2 of its existing drugs, reported Bloomberg Business. Patients using the combination drug in a late-stage clinical trial were able to reduce their blood sugar levels more than with either drug alone, according to the company. Federal regulators have requested further data.

Read more:

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up